logo
Sign InSign Up

BIO-TECHNE CORP (TECH)

Sector: Healthcare

Financial Fundamentals

findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for TECH, sign up here.

Income Statement

Revenue

$1.1bn

Gross Profit

$768.6m

Earning before Tax

$251.5m

Net Income

$224.2m

Net Income Common Shareholders

$224.2m

EPS

1.41

Balance Sheet

Cash

$130.1m

Debt

$555.7m

Assets

$2.7bn

Liabilities

$767.2m

Equity

$2.0bn

Enterprise Value

$12.6bn

Cash Flow Statement

Net Cash from Operations

$276.4m

Net Cash from Investing

$-0.4bn

Net Cash from Financing

$116.7m

Net Cash Flow

$-34.5m

Free Cash Flow

$225.4m

Free Cash Flow per Share

$1.43

Metrics

Price to Equity

54.44

Price to Equity (Damodaran)

54.72

Price to Book

6.21

Net Margin

0.20

Return on Equity

0.12

Return on Sales

0.23

Get immediate access to 5-years of reference grade data for TECH for free.

Sign up

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Company Info

Industry

Biotechnology

Employees

3,200

Address

614 McKinley Place N.E.
Minneapolis, MN 55413
United States

Phone

612 379 8854

Last Updated

2024-02-15

Available Data

Standardized Financial Statements

EOD Price History

Corporate Actions

Institutional Holdings

Insider Transactions

Sign up for free and get immediate access
logo

Radically accessible financial data

Contact Info

findl.com info@findl.com

Explore findl data

DocumentationSupport

Copyright © findl 2024. All rights reserved.

Terms & Use

Privacy Policy